Published in J Clin Psychopharmacol on December 01, 2002
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.89
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol (2011) 1.13
Prediction of cognitive decline in healthy older adults using fMRI. J Alzheimers Dis (2010) 1.12
Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm (Vienna) (2006) 0.99
PET radiopharmaceuticals for probing enzymes in the brain. Am J Nucl Med Mol Imaging (2013) 0.89
PET/CT in diagnosis of dementia. Ann N Y Acad Sci (2011) 0.89
Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 0.86
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr (2013) 0.85
Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET. Psychopharmacology (Berl) (2014) 0.82
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat (2007) 0.82
Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 0.80
Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats. Addict Biol (2012) 0.80
Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action. Alzheimers Res Ther (2012) 0.79
A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. Prim Care Companion CNS Disord (2013) 0.78
Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers. Eur J Clin Pharmacol (2015) 0.78
Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report. J Alzheimers Dis (2012) 0.77
Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging (2016) 0.76
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin Interv Aging (2017) 0.75
Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples. Br J Pharmacol (2010) 0.75
Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. Front Pharmacol (2016) 0.75
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Different metabolic responses of human brown adipose tissue to activation by cold and insulin. Cell Metab (2011) 3.40
Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation (2006) 3.12
Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet (2004) 2.91
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol (2008) 2.24
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Cardiac remodeling in a new pig model of chronic heart failure: Assessment of left ventricular functional, metabolic, and structural changes using PET, CT, and echocardiography. J Nucl Cardiol (2015) 2.10
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2004) 1.93
Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation (2008) 1.82
Neurological symptoms and natural course of xeroderma pigmentosum. Brain (2008) 1.78
Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology (2003) 1.70
Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging (2011) 1.63
Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography. Anesthesiology (2002) 1.62
Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med (2010) 1.61
Binge drinking in midlife and dementia risk. Epidemiology (2005) 1.61
Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci (2005) 1.58
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging (2008) 1.55
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse (2007) 1.46
Brain white matter expansion in human obesity and the recovering effect of dieting. J Clin Endocrinol Metab (2007) 1.46
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation (2004) 1.43
Absorption, distribution and excretion of intravenously injected (68)Ge/ (68)Ga generator eluate in healthy rats, and estimation of human radiation dosimetry. EJNMMI Res (2015) 1.38
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord (2002) 1.31
Effects of working-memory training on striatal dopamine release. Science (2011) 1.30
Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain (2003) 1.29
Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging (2011) 1.27
Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging (2003) 1.27
Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol (2007) 1.27
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology (2005) 1.19
Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord (2008) 1.15
Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology (2003) 1.14
Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) (2005) 1.14
Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology (2010) 1.13
High intensity exercise decreases global brain glucose uptake in humans. J Physiol (2005) 1.11
Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging (2014) 1.11
Altered dopamine D2 receptor binding in atypical facial pain. Pain (2003) 1.10
Increased brain fatty acid uptake in metabolic syndrome. Diabetes (2010) 1.10
C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse (2009) 1.10
Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol (2006) 1.07
Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage (2012) 1.07
Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer (2002) 1.07
Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage (2003) 1.07
64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol (2014) 1.06
Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord (2006) 1.05
Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain. Synapse (2015) 1.05
Skeletal muscle blood flow and oxygen uptake at rest and during exercise in humans: a pet study with nitric oxide and cyclooxygenase inhibition. Am J Physiol Heart Circ Physiol (2011) 1.04
Regulation of human skeletal muscle perfusion and its heterogeneity during exercise in moderate hypoxia. Am J Physiol Regul Integr Comp Physiol (2010) 1.04
Nuclear imaging of inflammation: homing-associated molecules as targets. EJNMMI Res (2013) 1.04
Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev (2002) 1.04
Comparison of exogenous adenosine and voluntary exercise on human skeletal muscle perfusion and perfusion heterogeneity. J Appl Physiol (1985) (2009) 1.03
In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res (2013) 1.03
Mobile phone affects cerebral blood flow in humans. J Cereb Blood Flow Metab (2006) 1.03
Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord (2004) 1.03
Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging (2002) 1.02
Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab (2008) 1.02
Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging (2005) 1.02
Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635-considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab (2006) 1.00
Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med (2013) 1.00
Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging (2005) 1.00
C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.00
Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail (2006) 0.98
Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis (2008) 0.98
Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry (2005) 0.97
Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med (2007) 0.97
Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men. Obes Res (2003) 0.97
Effects of a 902 MHz mobile phone on cerebral blood flow in humans: a PET study. Neuroreport (2003) 0.97
Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging (2012) 0.96